Skip to content
Evigrade
MajorAntianginal – late sodium current inhibitor×Non-dihydropyridine calcium channel blocker

Updated · Methodology

Mechanism

The liver and gut break down ranolazine mainly through the enzyme CYP3A4 and to a lesser extent through CYP2D6, and ranolazine is also a substrate of the transporter P-glycoprotein (P-gp) (ranolazine label, US Food and Drug Administration, FDA). Verapamil inhibits CYP3A4 and P-gp and can raise the levels of drugs mainly metabolised by CYP3A4 or transported by P-gp, which may increase or prolong their effects and adverse effects (verapamil summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Verapamil 120 mg three times daily increased steady-state ranolazine levels 2.2-fold (ranolazine SmPC, European Medicines Agency, EMA). The US label reports a 100% increase in ranolazine levels with ranolazine 750 mg twice daily (FDA). The European ranolazine SmPC classes verapamil as a P-gp inhibitor, while the US label classes it as a moderate CYP3A inhibitor (EMA, FDA). The higher the ranolazine level, the more frequent its dose-dependent adverse effects, such as nausea and dizziness, and the greater the prolongation of the heart-rate-corrected QT interval (QTc) (EMA).

Symptoms

The rise in ranolazine levels itself causes no symptoms. Dizziness, nausea and vomiting become more frequent as the ranolazine dose rises (ranolazine summary of product characteristics, SmPC, European Medicines Agency, EMA). Abnormal coordination, myoclonus, paraesthesia and tremor have also been reported, often starting after an increase in ranolazine dose or exposure (ranolazine label, US Food and Drug Administration, FDA). QT prolongation shows only on the electrocardiogram (ECG), but feeling faint or lightheaded and an irregular or fast heartbeat may be related to it (FDA).

Management

Limit ranolazine to 500 mg twice daily in patients taking moderate CYP3A inhibitors. The US ranolazine label names verapamil among them (ranolazine label, US Food and Drug Administration, FDA). This limit is below the maximum dose in both the US label, 1000 mg twice daily (FDA), and the European summary of product characteristics (SmPC), 750 mg twice daily (ranolazine SmPC, European Medicines Agency, EMA). According to the European SmPC, start ranolazine and increase its dose with caution in patients taking P-glycoprotein (P-gp) inhibitors, including verapamil, adjust the dose carefully and reduce it if needed (EMA). The combination itself is not contraindicated: ranolazine is an add-on to calcium antagonists when they are not enough or not tolerated (EMA). If dizziness, nausea or vomiting occur, the ranolazine dose may need to be reduced to 500 mg or 375 mg twice daily, and if the symptoms do not resolve, stop ranolazine (EMA). Other factors can also raise ranolazine exposure, such as renal impairment with creatinine clearance of 30–80 mL/min, older age, body weight of 60 kg or less, or New York Heart Association (NYHA) class III–IV heart failure. In patients with such factors, monitor for adverse effects more often and reduce the dose or, if needed, stop ranolazine (EMA). The documents do not say how ranolazine changes verapamil levels. Ranolazine weakly inhibits CYP3A4 (EMA), and CYP3A4 inhibitors can raise verapamil levels, so monitor patients who take them (verapamil SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Ranolazine

Other interactions with Verapamil